Janet Gunzner-Toste, Ph.D., M.B.A., is Senior Vice President of Operations. In this role, she oversees Portfolio Management & Operations, Information Technology and Quality & Compliance. Most recently, she served as the Chief Operating Officer of Exavir Therapeutics. She also served as the Vice President of Program Management at Eidos Therapeutics, a subsidiary of BridgeBio Pharma, Inc. Earlier in her career, Dr. Gunzner-Toste worked as the Senior Director of Program and Alliance Management at Nektar Therapeutics, as well as a Senior Project Manager in Portfolio Management & Operations and Chemistry Team Leader in Research at Genentech. Before her tenure at Genentech, she served as a Senior Research Chemist at Merck & Co., Inc. Dr. Gunzner-Toste’s contributions to the scientific community are exemplified by her co-authorship of over 30 published papers in peer-reviewed scientific journals and her co-inventorship of more than 30 US and worldwide patent applications. Dr. Gunzner-Toste earned her B.A. in chemistry from Reed College and her Ph.D. in chemistry from The Scripps Research Institute. She completed postdoctoral training at Stanford University, supported by a postdoctoral fellowship from the National Institutes of Health (NIH). Additionally, Dr. Gunzner-Toste holds an M.B.A. degree from University of California, Berkeley, Haas School of Business.